Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two plixorafenib abstracts have been ...

Shadow Power, a leader in customer energy resource (CERs) management, proudly announces that its platform is now OpenADR 2.0b certified. This milestone reinforces Shadow Power's ability to transform ...

On this episode of Dinner SOS, Chris and Shilpa are here to help George tackle plant-based proteins. ON THIS WEEK’S episode ...

and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as the most likely suitor.

Biotheryx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a son of sevenless homolog 1 (SOS1) targeting moiety ...

Does RAF show translocation due to unlabeled SOS2 in the SOS1 knockout cells that do not have the SOS rescue construct? These are important to assess whether the information picked up by the TE ...

Methods for the construction of SOS and RAF plasmids and the establishment of SOS1 knockout HeLa cells have been previously described (Nakamura et al., 2017). The SOS1 knockout cell was confirmed to ...